Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States and many other parts of the world. Its prevalence continues to rise—currently affecting ~20 to 30% of adults and 10% of children in the United States. NAFLD represents a wide spectrum of conditions ranging from fatty liver, which in general follows a benign nonprogressive clinical course, to steatohepatitis or NASH, a more serious form of NAFLD that may progress to cirrhosis and end-stage liver disease. Although currently a combination of noninvasive clinically available laboratory and imaging tests may help in the diagnostic evaluation of a patient with suspected NAFLD, a liver biopsy remains the only reliable way to precisely diagnose NASH and establish the severity of liver injury and presence of fibrosis. It also provides important information regarding prognosis as well as response to therapeutic interventions. However, a liver biopsy is an invasive and costly procedure, which is poorly suited as a diagnostic test for a condition that may affect about one-third of the U.S. population. This review provides a concise overview of the role of liver biopsy versus noninvasive diagnostic tools for the differentiation of fatty liver from nonalcoholic steatohepatitis as well as for the determination of presence and extent of fibrosis. In particular, this review focuses on the methods currently available in daily clinical practice in hepatology and touches briefly on potential future markers under investigation.

KEYWORDS

Fatty liver - nonalcoholic steatohepatitis - liver biopsy - noninvasive diagnostic test - biomarkers

REFERENCES

• 1 Angulo P. Nonalcoholic fatty liver disease.  N Engl J Med. 2002;  346 1221-1231
• 2 Wieckowska A, Feldstein A E. Nonalcoholic fatty liver disease in the pediatric population: a review.  Curr Opin Pediatr. 2005;  17 636-641
• 3 Adams L A, Lymp J F, St Sauver J et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.  Gastroenterology. 2005;  129 113-121
• 4 Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116 1413-1419
• 5 Ekstedt M, Franzen L E, Mathiesen U L et al.. Long-term follow-up of patients with NAFLD and elevated liver enzymes.  Hepatology. 2006;  44 865-873
• 6 Dam-Larsen S, Franzmann M, Andersen I B et al.. Long term prognosis of fatty liver: risk of chronic liver disease and death.  Gut. 2004;  53 750-755
• 7 Wieckowska A, McCullough A J, Feldstein A E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.  Hepatology. 2007;  46(2) 582-589
• 8 Ramesh S, Sanyal A J. Hepatitis C and nonalcoholic fatty liver disease.  Semin Liver Dis. 2004;  24 399-413
• 9 Ludwig J, Viggiano T R, McGill D B, Oh B J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
• 10 Yeh M M, Brunt E M. Pathology of nonalcoholic fatty liver disease.  Am J Clin Pathol. 2007;  128 837-847
• 11 Brunt E M. Pathology of fatty liver disease.  Mod Pathol. 2007;  20(suppl 1) S40-S48
• 12 Schwimmer J B, Behling C, Newbury R et al.. Histopathology of pediatric nonalcoholic fatty liver disease.  Hepatology. 2005;  42 641-649
• 13 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.  Hepatology. 2005;  41 1313-1321
• 14 Brunt E M, Janney C G, Di Bisceglie A M, Neuschwander-Tetri B A, Bacon B R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol. 1999;  94 2467-2474
• 15 Adams L A, Sanderson S, Lindor K D, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.  J Hepatol. 2005;  42 132-138
• 16 Coton T, Matton T, Pecarrere J L, Monchy D, Debonne J M. Interobserver reproducibility of the Knodell score and the Metavir score in chronic viral hepatitis C: results of 60 liver biopsies.  Gastroenterol Clin Biol. 2001;  25 915-916
• 17 Ong J P, Younossi Z M. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease.  Clin Liver Dis. 2005;  9 617-634 vi
• 18 Adams L A, Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.  Clin Liver Dis. 2007;  11 25-35
• 19 Ratziu V, Bugianesi E, Dixon J et al.. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability.  Aliment Pharmacol Ther. 2007;  26 821-830
• 20 Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies.  J Hepatol. 1986;  2 165-173
• 21 Ratziu V, Charlotte F, Heurtier A et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease.  Gastroenterology. 2005;  128 1898-1906
• 22 Merriman R B, Ferrell L D, Patti M G et al.. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.  Hepatology. 2006;  44 874-880
• 23 Janiec D J, Jacobson E R, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies.  Obes Surg. 2005;  15 497-501
• 24 Younossi Z M, Gramlich T, Liu Y C et al.. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.  Mod Pathol. 1998;  11 560-565
• 25 Adams L A, Talwalkar J A. Diagnostic evaluation of nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40 S34-S38
• 26 Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees.  J Clin Epidemiol. 2001;  54 945-951
• 27 Nomura K, Yano E, Shinozaki T, Tagawa K. Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups.  J Occup Health. 2004;  46 423-428
• 28 Ipekci S H, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis.  J Clin Gastroenterol. 2003;  36 371
• 29 Mofrad P, Contos M J, Haque M et al.. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.  Hepatology. 2003;  37 1286-1292
• 30 Kunde S S, Lazenby A J, Clements R H, Abrams G A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women.  Hepatology. 2005;  42 650-656
• 31 Suzuki A, Lymp J, Sauver J S, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis.  Liver Int. 2006;  26 1209-1216
• 32 Lindor K D, Kowdley K V, Heathcote E J et al.. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.  Hepatology. 2004;  39 770-778
• 33 Brunt E M, Neuschwander-Tetri B A, Oliver D, Wehmeier K R, Bacon B R. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.  Hum Pathol. 2004;  35 1070-1082
• 34 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 35 Dixon J B, Bhathal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.  Gastroenterology. 2001;  121 91-100
• 36 Palekar N A, Naus R, Larson S P, Ward J, Harrison S A. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.  Liver Int. 2006;  26 151-156
• 37 Gholam P M, Flancbaum L, Machan J T, Charney D A, Kotler D P. Nonalcoholic fatty liver disease in severely obese subjects.  Am J Gastroenterol. 2007;  102 399-408
• 38 Poynard T, Ratziu V, Charlotte F et al.. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.  BMC Gastroenterol. 2006;  6 34
• 39 Zein C O, Edmison J, Schluchter M, Feldstein A E, Zein N N, McCullough A JA. NASH predictive index (NPI) for use in patients with nonalcoholic fatty liver disease.  Hepatology. 2007;  46 747A
• 40 Ratziu V, Giral P, Charlotte F et al.. Liver fibrosis in overweight patients.  Gastroenterology. 2000;  118 1117-1123
• 41 Ratziu V, Massard J, Charlotte F et al.. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.  BMC Gastroenterol. 2006;  6 6
• 42 Angulo P, Hui J M, Marchesini G et al.. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.  Hepatology. 2007;  45 846-854
• 43 Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.  Liver Int. 2005;  25 779-786
• 44 Lydatakis H, Hager I P, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease.  Liver Int. 2006;  26 864-871
• 45 Rosenberg W M, Voelker M, Thiel R et al.. Serum markers detect the presence of liver fibrosis: a cohort study.  Gastroenterology. 2004;  127 1704-1713
• 46 Guha I N, Parkes J, Roderick P et al.. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers.  Hepatology. 2008;  47 455-460
• 47 Mishra P, Younossi Z M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD).  Am J Gastroenterol. 2007;  102 2716-2717
• 48 Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver.  AJR Am J Roentgenol. 2007;  189 W320-W323
• 49 Hamaguchi M, Kojima T, Itoh Y et al.. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.  Am J Gastroenterol. 2007;  102 2708-2715
• 50 Ryan C K, Johnson L A, Germin B I, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation.  Liver Transpl. 2002;  8 1114-1122
• 51 Mottin C C, Moretto M, Padoin A V et al.. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients.  Obes Surg. 2004;  14 635-637
• 52 Thomas E L, Hamilton G, Patel N et al.. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study.  Gut. 2005;  54 122-127
• 53 Szczepaniak L S, Babcock E E, Schick F et al.. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo.  Am J Physiol. 1999;  276 E977-E989
• 54 Browning J D, Szczepaniak L S, Dobbins R et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.  Hepatology. 2004;  40 1387-1395
• 55 Saadeh S, Younossi Z M, Remer E M et al.. The utility of radiological imaging in nonalcoholic fatty liver disease.  Gastroenterology. 2002;  123 745-750
• 56 Castera L, Pawlotsky J M. Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.  MedGenMed. 2005;  7 39
• 57 Foucher J, Castera L, Bernard P H et al.. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations.  Eur J Gastroenterol Hepatol. 2006;  18 411-412
• 58 Oliveira C P, da Costa Gayotto L C, Tatai C et al.. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet.  J Cell Mol Med. 2002;  6 399-406
• 59 Roskams T, Yang S Q, Koteish A et al.. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease.  Am J Pathol. 2003;  163 1301-1311
• 60 Day C P. Pathogenesis of steatohepatitis.  Best Pract Res Clin Gastroenterol. 2002;  16 663-678
• 61 Wanless I R, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.  Semin Liver Dis. 2004;  24 99-106
• 62 Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T. Blood oxidative stress markers are unreliable markers of hepatic steatosis.  Aliment Pharmacol Ther. 2006;  23 91-98
• 63 Chalasani N, Deeg M A, Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2004;  99 1497-1502
• 64 Horoz M, Bolukbas C, Bolukbas F F et al.. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.  BMC Gastroenterol. 2005;  5 35
• 65 Solga S F, Alkhuraishe A, Cope K et al.. Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations.  Biomarkers. 2006;  11 174-183
• 66 Diehl A M. Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis.  Alcohol Clin Exp Res. 2001;  25 8S-14S
• 67 Diehl A M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease.  Clin Liver Dis. 2004;  8 619-638 x
• 68 Abiru S, Migita K, Maeda Y et al.. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis.  Liver Int. 2006;  26 39-45
• 69 Feldstein A E, Werneburg N W, Canbay A et al.. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway.  Hepatology. 2004;  40 185-194
• 70 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.  Hepatology. 2004;  40 46-54
• 71 Li Z, Yang S, Lin H et al.. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.  Hepatology. 2003;  37 343-350
• 72 Xu H, Uysal K T, Becherer J D, Arner P, Hotamisligil G S. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity.  Diabetes. 2002;  51 1876-1883
• 73 Haukeland J W, Damas J K, Konopski Z et al.. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.  J Hepatol. 2006;  44 1167-1174
• 74 Hui J M, Farrell G C, Kench J G, George J. High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD.  Hepatology. 2004;  39 1458-1459
• 75 Feldstein A E, Canbay A, Angulo P et al.. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.  Gastroenterology. 2003;  125 437-443
• 76 Feldstein A E, Canbay A, Guicciardi M E, Higuchi H, Bronk S F, Gores G J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice.  J Hepatol. 2003;  39 978-983
• 77 Feldstein A E, Gores G J. Apoptosis in alcoholic and nonalcoholic steatohepatitis.  Front Biosci. 2005;  10 3093-3099
• 78 Feldstein A E, Werneburg N W, Li Z, Bronk S F, Gores G J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization.  Am J Physiol Gastrointest Liver Physiol. 2006;  290 G1339-G1346
• 79 Li Z, Berk M, McIntyre T M, Gores G J, Feldstein A E. The lysosomal-mitochondrial axis in free fatty acids induced hepatic lipotoxicity.  Hepatology. 2008;  47 1495-1503
• 80 Wieckowska A, Zein N N, Yerian L M, Lopez A R, McCullough A J, Feldstein A E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.  Hepatology. 2006;  44 27-33
• 81 Wieckowska A, Lopez A R, Zein N N, McCullough A J, Feldstein A E. Noninvasive assessment of hepatocyte apoptosis in nonalcoholic fatty liver disease: a multi-center validation study.  Gastroenterology. 2007;  132 A729
• 82 Day C P. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease.  Liver Int. 2006;  26 1021-1028
• 83 Huang H, Shiffman M L, Cheung R C et al.. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.  Gastroenterology. 2006;  130 1679-1687